



Living Cell Technologies Limited Company Announcement

Appendix 4C Quarterly Cash Flow Report 31 March 2012

30 April 2012: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), announced today the quarterly cash flow report for the quarter ended 31 March 2012. The Appendix 4C is attached. The cash balance at the end of the quarter was \$2,662,000 compared to \$2,487,000 at 31 December 2011. This increase reflects the services fee charged to Diatranz Otsuka Limited (DOL) for the continuing development cost of DIABECCELL[®], partially offset by the cost of developing NTCELL for the treatment of Parkinson's disease.

Net operating cash flow in the quarter was \$95,000 compared to (\$296,000) last quarter. Receipts from customers were \$1,868,000 reflecting the services provided to DOL (last quarter \$1,257,000). Expenditure included \$79,000 on research and development (\$984,000 last quarter) for preclinical studies of NTCELL. This reduction is due to R&D for DIABECCELL being charged to DOL in the services fee. Cash received from grants was \$144,000 (\$231,000 last quarter).

Capital expenditure was \$0 in the quarter, compared to \$0 last quarter as DOL is investing in fixed assets.

- Ends -

For further information: www.lctglobal.com

At the company: Dr Andrea Grant, Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 0785 421 agrant@lctglobal.com John Cowan, Head of Finance & Administration Tel: +64 9 276 2690 Mobile: +64 21 469000 jcowan@lctglobal.com	Media enquiries: Sally Raudon Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 402 502 sallyr@botica.co.nz
--	---

About Living Cell Technologies

LCT leads the world in cell transplant research and has implemented a business model that supports the discovery and advancement of products through preclinical and early clinical

+ See chapter 19 for defined terms.

development. LCT aims to secure a major pharmaceutical partner to co-develop products through Phase II and pivotal studies, and ultimately market introduction. Value is returned to LCT principally through an ownership share of downstream product profits. LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Living Cell Technologies Limited

ABN

14 104 028 042

Quarter ended ("current quarter")

31 March 2012

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (...9... months) \$A'000
1.1	Receipts from customers	1,868	3,129
1.2	Payments for (a) staff costs	(262)	(828)
	(b) advertising and marketing	(25)	(99)
	(c) research and development	(79)	(1,784)
	(d) leased assets	-	-
	(e) other working capital	(1,596)	(3,126)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	45	104
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other (government grants received)	144	605
Net operating cash flows		95	(1,999)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (....9... months) \$A'000
1.8 Net operating cash flows (carried forward)	95	(1,999)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	(41)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	2
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	0	39
1.14 Total operating and investing cash flows	95	(2,038)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	150
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	(5)
1.20 Other (provide details if material)	-	-
Net financing cash flows	0	145
Net increase (decrease) in cash held	95	(1,893)
1.21 Cash at beginning of quarter/year to date	2,487	4,505
1.22 Exchange rate adjustments to item 1.20	80	50
1.23 Cash at end of quarter	2,662	2,662

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	102
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Salaries & fees paid to directors for the quarter

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

NIL

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.